IQVIA Announces Offering of Senior Secured Notes
2023年11月14日 - 11:07PM
ビジネスワイヤ(英語)
IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced
that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or
“Borrower”), intends to raise $500,000,000 through an offering of
senior secured notes due 2029 (the “Notes”).
Substantially concurrently with the closing of this offering,
the Borrower intends to amend its senior secured credit facilities
(the “Credit Agreement Amendment”) to provide for a new term B loan
of approximately $1,250 million (the “New Term Loan B”).
The proceeds from the Notes offering, together with the proceeds
from the New Term Loan B, are expected to be used to repay certain
of the outstanding term loans under the Borrower’s senior secured
credit facilities and to pay fees and expenses related to the
Issuer’s Notes offering and the Borrower’s Credit Agreement
Amendment. The consummation of the Notes offering is subject to
market and other customary conditions. There can be no guarantee
that the Credit Agreement Amendment will be entered into or that
the New Term Loan B will be obtained on the anticipated terms or at
all. The Credit Agreement Amendment and the New Term Loan B are not
conditioned on the consummation of the Notes offering, and the
Notes offering is not conditioned on the consummation of the Credit
Agreement Amendment or the incurrence of the New Term Loan B.
Following the consummation of the Notes offering and the closing
of the New Term Loan B, the Company intends to enter into one or
more currency swap agreements to hedge exposure to USD-denominated
indebtedness created by the Notes and the New Term Loan B. There
can be no assurances that the Company will enter into any such
currency swap agreements, and the closing of the Notes offering and
the consummation of the New Term Loan B are not conditioned on the
entry into any currency swap agreements.
Certain statements in this press release are forward-looking
statements. These statements involve a number of risks,
uncertainties and other factors, including the Company’s potential
entry into one or more currency swap agreements, failure to
consummate the Notes offering, the failure to execute the Credit
Agreement Amendment and potential changes in market conditions that
could cause actual results to differ materially.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the Notes, nor shall there be any
offer, solicitation or sale of the Notes in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful. The Notes to be offered have not been registered under
the Securities Act of 1933, as amended (the “Securities Act”), or
the securities laws of any other jurisdiction and may not be
offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the
Securities Act. The Notes are being offered only to persons
reasonably believed to be qualified institutional buyers in
reliance on Rule 144A under the Securities Act and to certain
non-U.S. persons outside the United States in reliance on
Regulation S under the Securities Act. Any offer of the Notes will
be made only by means of a private offering memorandum.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected IntelligenceTM delivers powerful
insights with speed and agility — enabling customers to accelerate
the clinical development and commercialization of innovative
medical treatments that improve healthcare outcomes for patients.
With approximately 87,000 employees, IQVIA conducts operations in
more than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures.
IQVIAFIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113425130/en/
Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828
IQVIA (NYSE:IQV)
過去 株価チャート
から 8 2024 まで 9 2024
IQVIA (NYSE:IQV)
過去 株価チャート
から 9 2023 まで 9 2024